Amylyx Pharmaceuticals, Inc. cotiza a 26.85 USD y tiene una capitalización bursátil de $3.4B. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagoni…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | $-0.39 | $-0.37 | $-0.30 |
| Estimado | $-0.36 | $-0.36 | $-0.34 | $-0.34 |
| Sorpresa | — | -8.3% | -8.8% | +11.8% |
| Métrica | AMLX | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -47.4% | -40.4% | -7.0% |
| ROA | -43.5% | -32.0% | -11.5% |
| Current Ratio | 14.27 | 2.84 | +11.43 |
| Debt / Equity | — | 0.28 | — |